

MPP prioritised and watchlist products

MARCH 2025



HIV

- cabotegravir LA ViiV
- lenacapavir Gilead
- MK-8527 MSD
- islatravir MSD
- GS-1720 Gilead
- GS-4182 Gilead
- cabotegravir 4-monthly ViiV
- doravirine MSD
- TAF/EVG insert Conrad
- ulonivirine MSD
- VH4524184 ViiV
- VH4011499 ViiV



TUBERCULOSIS

- quabodepistat Otsuka
- alpipectir GSK
- bedaquiline long-acting Janssen
- delpazolid LegoChem BioSciences
- ganfeborole GSK
- macozinone EPFL
- sudapyridine Shanghai Jiatan Biotech



FOCUS ON CHILDREN

RESPIRATORY SYNCYTIAL VIRUS

- nirsevimab AstraZeneca/Sanofi
- clesrovimab MSD

MALARIA

- MicroCoat AS/AQ FluidPharma

LOW-GRADE GLIOMAS

- dabrafenib/trametinib Novartis

CYSTIC FIBROSIS

- elexacaftor/ivacaftor/tezacaftor Vertex

HIV POST-NATAL PROPHYLAXIS

- Monoclonal antibodies Multiple innovators



ONCOLOGY

MULTIPLE CANCER INDICATIONS

- Immune checkpoint inhibitors Multiple innovators
- including pembroliuzumab MSD

LUNG CANCER

- aumolertinib Hansoh Pharma
- osimertinib Astrazeneca
- adagrasib Bristol Myers Squibb
- lazertinib Janssen
- sotorasib Amgen

BREAST CANCER

- abemaciclib Eli Lilly
- ribociclib Novartis
- trastuzumab SQ Roche

CHRONIC LYMPHOCYTIC LEUKAEMIA

- zanubrutinib Beigene

PROSTATE CANCER

- apalutamide Janssen
- darolutamide Bayer



DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

- Multiple innovators
- including semaglutide Novo Nordisk
- tirzepatide Eli Lilly
- orforglipron Eli Lilly
- retatrutide Eli Lilly

Insulin analogues

Multiple innovators

cardiovascular fixed-dose combination therapies

Multiple innovators



VIRAL HEPATITIS

HEPATITIS C

- bemnifosbuvir Atea
- ruzasvir Atea

HEPATITIS B

- bepirovirsen GSK



PANDEMIC & EPIDEMIC THREATS

- baloxavir marboxil Roche

PRIORITY LIST

WATCHLIST